Hengrui Pharmaceuticals Expands Overseas Again via NewCo Model, Licensing Cardiac Myosin Inhibitor HRS-1893 to US-Based Braveheart Bio in $1 Bn Deal

2025-09-05 2025-09-05

Sign In or Start Free Trial To Get Full Access.

On-the-ground China market Intelligence for professionals. Exclusive Insights you don't see anywhere else.